Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

View Full Paper
Ask AI
Bookmark
Share

Authors

CRChristine E. RyanVWVictoria WangMSMitchell R. Smith

Discussion

Loading...

Member takes

Overview

Randomized trial examined PET/CT scan and bone marrow biopsy impact on progression-free survival in MCL, suggesting need for early treatment adjustments.

Key Points

  • Evaluate the prognostic significance of response assessments in patients with Mantle Cell Lymphoma receiving frontline therapy.
  • Analyzed results from the ECOG-ACRIN E1411 randomized phase 2 trial on MCL treatments.
  • Investigated mid-induction PET/CT scan and end-of-induction bone marrow biopsy prognoses.
  • Used Kaplan-Meier method and Cox proportional hazards models for analysis.
  • Interim PET-positive patients had a median progression-free survival of 4.9 years compared to 7.4 years for PET-negative patients.
  • EOI bone marrow biopsy showed low involvement rates, suggesting few patients needed additional procedures.
  • Trends in PFS differences based on EOI bone marrow status highlight potential for treatment strategy adjustments.

Cite This Study

Ryan et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9c5https://doi.org/10.1182/blood-2025-3581
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank2025
  2. 2Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP2019 · 9 citations
  3. 3Bone marrow biopsy superiority over PET / CT in predicting progression‐free survival in a homogeneously‐treated cohort of diffuse large B‐cell lymphoma2017 · 18 citations
  4. 4OUTCOME OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET‐GUIDED APPROACH2019 · 1 citations
  5. 5In mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value2026